Natco Pharma has announced a board meeting to review the financial results for the quarter and half-year.

The U.S.

FDA recently concluded an inspection at its Kothur facility, resulting in 7 observations in Form-483. The company is confident about resolving these issues within the given timeline and remains committed to cGMP compliance and supplying high-quality pharma products globally.

Natco continues to focus on oncology and limited competition molecules in the US, with approvals from multiple global regulators supporting its presence in 50+ markets.